Zantac Colorectal Cancer Lawyers Sue Sanofi-Aventis US LLC and Boehringer Ingelheim Pharmaceuticals Inc.
Thousands of Americans are suspected of developing digestive tract cancers including, colon or rectal cancer, following sustained use of Zantac. The heartburn medication has now been recalled from the U.S. marketplace.
One such individual diagnosed with colorectal cancer decided to contact a lawyer. He has filed suit based on the manufacturer’s failure to warn of cancer risks. The plaintiff claimed he would not have consumed Zantac for an extended period of time had he been provided the warning appropriate under the law.
Indeed, many heartburn patients have continued taking Zantac, or other forms of generic Ranitidine, for many months or years. Unbeknownst to these patients, they may have been exposed to a dangerous carcinogen.
As a result of the failure to warn, this plaintiff was diagnosed with Stage 3 colon cancer. The cancer often begins with polyps in the colon or rectum. Also known as bowel cancer, Zantac colorectal cancer lawyers estimate nearly 5% of the population develop this cancer over their lifetime.
Sanofi-Aventis US LLC and Boehringer Ingelheim Pharmaceuticals Inc. face Zantac colorectal cancer lawsuits
The Zantac colorectal cancer lawsuits filed by plaintiffs such as this allege NDMA impurity associated with the Over The Counter pharmaceutical is to blame. Anticipated settlement funds are intended to compensate physical pain and suffering, as well as medical bills, lost wages and more.
Click here for additional information on our Zantac lawyers.
NDMA contamination can be found throughout the environment. However, when it is ingested or forms in the human body, it can be fatal.
Disturbingly, scientific evidence suggests Zantac may contain, or cause production of, carcinogenic levels of NDMA. The primary digestive tract cancers associated with exposure to NDMA in Zantac include rectal and colon cancer.
Contact our Zantac colorectal cancer lawyers for a free case review.
